Drug intelligence / Profile preview

Lactobacillus plantarum ATG-K2

Development stage: Phase 1
Lead developer: Yuhan
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Vaginal

Overview

LABTHERA-001 is an investigational live biotherapeutic product containing the probiotic strain *Lactobacillus plantarum* ATG-K2, which was originally isolated from Kimchi. [3] Developed by AtoGen (a subsidiary of Yuhan Corporation), it is formulated as an intravaginal capsule for the treatment of bacterial vaginosis (BV). [1, 4, 9, 12] In preclinical studies, ATG-K2 demonstrated the ability to inhibit the growth and biofilm formation of *Gardnerella vaginalis*, a primary pathogen in BV. [8] A Phase 1 clinical trial has been completed to evaluate the safety, tolerability, and acceptability of LABTHERA-001 in healthy female volunteers. [1, 4]

Beyond the preview

Go deeper on Lactobacillus plantarum ATG-K2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus plantarum ATG-K2.

Explore the full profile